Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1–2 trialsAlexander Drilon, Robert C. Doebele, Matthew Krebs et al.|The Lancet Oncology|2019Cited by 537
Increases of Amphiregulin and Transforming Growth Factor-α in Serum as Predictors of Poor Response to Gefitinib among Patients with Advanced Non–Small Cell Lung CancersNobuhisa Ishikawa, Yusuke Nakamura, Yataro Daigo et al.|Cancer Research|2005Cited by 192